KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Current Deferred Revenue (2017 - 2025)

Guardant Health's Current Deferred Revenue history spans 9 years, with the latest figure at $50.8 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 22.0% year-over-year to $50.8 million; the TTM value through Dec 2025 reached $50.8 million, up 22.0%, while the annual FY2025 figure was $50.8 million, 22.0% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $50.8 million at Guardant Health, down from $56.4 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $56.4 million in Q3 2025 and bottomed at $7.3 million in Q3 2021.
  • The 5-year median for Current Deferred Revenue is $20.0 million (2022), against an average of $25.4 million.
  • The largest annual shift saw Current Deferred Revenue fell 29.96% in 2021 before it skyrocketed 134.44% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $11.3 million in 2021, then soared by 53.66% to $17.4 million in 2022, then surged by 31.59% to $22.9 million in 2023, then skyrocketed by 81.66% to $41.6 million in 2024, then grew by 22.0% to $50.8 million in 2025.
  • Per Business Quant, the three most recent readings for GH's Current Deferred Revenue are $50.8 million (Q4 2025), $56.4 million (Q3 2025), and $54.4 million (Q2 2025).